Access cutting-edge open angle glaucoma (oag) treatment through this phase 4 clinical trial at a research site in Bloomington. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Bloomington location
Preparing your pre-screening questions…
Access open angle glaucoma (oag) specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related open angle glaucoma (oag) treatment provided free
Check if you qualify for this open angle glaucoma (oag) clinical trial in Bloomington, IN
No-Cost Study Care
Local to Bloomington
Convenient for IN residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The purpose of this study is to compare how two FDA-approved eye drops: netarsudil (Rhopressa) and timolol, protect nerve cells in the eye of adults with open-angle glaucoma. Both medications lower pressure inside the eye, but researchers want to learn if Rhopressa is more effective at slowing down or preventing the loss of retinal ganglion cells. These cells are essential for sight because they carry visual signals from the eye to the brain. Participants in this study will complete a total of 6 study visits over 12 months: * Participants will spend 6 months using Rhopressa eye drops and 6 months using Timolol eye drops. The order of the two eye drops will be chosen randomly. * At scheduled study visits, researchers will examine participants' eyes and measure eye pressure. * Researchers will take detailed pictures of the back of the eye using a specialized high-resolution camera called adaptive optics optical coherence tomography (AO-OCT). * Participants will also complete specialized visual field testing to measure eye function. Researchers will count and track individual nerve cells over time to determine if one medication offers better protection against cell loss than the other.
Sponsor: Brett King
Yes, this clinical trial (NCT07847073) has an active research site in Bloomington, IN that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for open angle glaucoma (oag) treatment options in Bloomington, IN, this clinical trial (NCT07847073) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Bloomington research site is actively enrolling participants for this phase 4 clinical trial. You'll receive care from experienced open angle glaucoma (oag) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all open angle glaucoma (oag) clinical trials near you to find additional studies recruiting in your area.
See all pulmonary embolism clinical trials recruiting in Bloomington — not just this study.
Browse Pulmonary Embolism Trials in Bloomington →